IL1RL1 and leukemia: Overall, these findings indicated that anti-Il1rl1 T-BsAb using murine antibodies in an immunocompetent model and humanized antibodies in a human xenograft model effectively inhibit both leukemia growth and the tolerogenic immune microenvironment in immunocompetent and humanized pre-clinical models.